← Back to Search

Cancer Vaccine

Vaccine Education for Pneumonia (PVI Trial)

N/A
Recruiting
Led By Jason Woloski, MD
Research Sponsored by Geisinger Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients admitted to inpatient Family Medicine service with Type I and II Diabetes
Be between 18 and 65 years old
Must not have
Patients with pneumonia inpatient diagnosis at time of recruitment
Patients with any active infections
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion of up to one year.
Awards & highlights

Summary

This trial aims to see if educating patients about the Prevnar 20 pneumonia vaccine will increase the number of patients who choose to receive it while in the hospital. The study will also look at other

Who is the study for?
This trial is for patients over 65 or those with diabetes, COPD, or asthma who haven't had a pneumonia vaccine and are currently in the hospital under Family Medicine care. It's to see if extra education about the Prevnar 20 vaccine increases how many decide to get vaccinated before leaving the hospital.
What is being tested?
The study tests whether providing additional information on the Prevnar 20 Pneumococcal vaccine by medical staff influences patients' willingness to receive it during their hospital stay. The focus is on understanding patient acceptance rates and reasons behind their decision.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am hospitalized and have Type I or II Diabetes.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am currently hospitalized with a diagnosis of pneumonia.
Select...
I currently have an active infection.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion of up to one year.
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion of up to one year. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of patients accepting the Prevnar 20 Pneumococcal vaccine after receiving pharmacy-led education intervention during standard care.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: TreatmentExperimental Treatment1 Intervention
Patients randomized into this arm RECEIVE Pneumococcal vaccine education prior to given the option to accept or refuse the vaccine.
Group II: ControlActive Control1 Intervention
Patients randomized into this arm DO NOT RECEIVE Pneumococcal vaccine education prior to given the option to accept or refuse the vaccine.

Find a Location

Who is running the clinical trial?

Geisinger ClinicLead Sponsor
153 Previous Clinical Trials
1,974,056 Total Patients Enrolled
Jason Woloski, MDPrincipal InvestigatorGeisinger Clinic
1 Previous Clinical Trials
15 Total Patients Enrolled
~67 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top